Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25712730 | 0.86 | TSHR (0.31) | TSHR | |
| SCHEMBL26050121 | 0.80 | TSHR (0.33) | TSHR | |
| SCHEMBL24399540 | 0.78 | — | — | |
| SCHEMBL24399538 | 0.76 | TSHR (0.31) | TSHR | |
| SCHEMBL25712726 | 0.76 | TSHR (0.31) | TSHR | |
| SCHEMBL25712729 | 0.76 | TSHR (0.31) | TSHR | |
| SCHEMBL5222623 | 0.74 | — | — | |
| SCHEMBL24794964 | 0.73 | — | — | |
| SCHEMBL8383906 | 0.70 | — | — | |
| SCHEMBL6848509 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031179-B2 | Methods and compositions for reducing nucleotide impurities | Singular Genomics Systems, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023212369-A1 | NUCLEOTIDE CYCLIC CLEAVABLE MOIETIES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11795505-B2 | Nucleic acid delivery scaffolds | Singular Genomics Systems, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023172665-A2 | NUCLEIC ACID DELIVERY SCAFFOLDS | Singular Genomics Systems, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230242571-A1 | SILICON CONTAINING MODIFIED NUCLEOTIDE ANALOGS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-03 | — | — | US | disclosed |
| US-20230203579-A1 | NANOARRAYS AND METHODS OF USE THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230193361-A1 | METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID SEQUENCING | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-22 | — | — | US | disclosed |
| WO-2023107673-A2 | CLEAVABLE DISULFIDE LINKERS AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022271970-A1 | METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID SEQUENCING | Singular Genomics Systems, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220396834-A1 | NANOARRAYS AND METHODS OF USE THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-12-15 | — | — | US | disclosed |
| US-20220136048-A1 | METHODS AND COMPOSITIONS FOR REDUCING NUCLEOTIDE IMPURITIES | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-05-05 | — | — | US | disclosed |
| WO-2022094415-A1 | METHODS AND COMPOSITIONS FOR REDUCING NUCLEOTIDE IMPURITIES | Singular Genomics Systems, Inc. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242571-A1 | SILICON CONTAINING MODIFIED NUCLEOTIDE ANALOGS | NSUN2, DCLRE1A, POLI | TSHR 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.